IDDF2020-ABS-0059 Safety and efficacy of sofosbuvir/velpatasvir (SOF/VEL) in pediatric patients 6 to < 18 years old with chronic hepatitis C (CHC) infection

Maureen Jonas,Rene Romero,Etienne Sokal,Philip Rosenthal, Gabriella Verucchi,Chuan-Hao Lin,Jessica Wen,Michael Narkewicz,Sanjay Bansal,Jiang Shao,Sean Hsueh,Anuj Gaggar,Kathryn Kersey,Carol Yee Kwan Chan,Regino Gonzalez-Peralta,Daniel Leung,William Balistreri,Karen Murray,Kathleen Schwarz

Gut（2020）

引用 4|浏览15

暂无评分

摘要

Background DAA regimens have been approved for CHC treatment in 12 to Methods Patients 6 to Results 102 patients 12 to 15%) were headache, fatigue, and nausea in adolescents and vomiting, cough and headache in 6 to Conclusions In patients 6 to

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要